CStone Pharmaceuticals (HK:2616)
:2616
Want to see HK:2616 full AI Analyst Report?
2616 Stock Chart & Stats
HK$5.34
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$5.34
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$3.06 - HK$13.15
Previous CloseN/A
Volume1.16M
Average Volume (3M)19.75M
Market Cap
HK$12.38B
Enterprise ValueHK$10.11B
Total Cash (Recent Filing)HK$919.09M
Total Debt (Recent Filing)HK$348.67M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Aug 20, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding1,600,249,100
10 Day Avg. Volume13,736,900
30 Day Avg. Volume19,747,038
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)10.65
Price to Sales (P/S)24.38
P/FCF Ratio-20.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$9.87Price Target Upside84.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)HK$468.24M
Bulls Say, Bears Say
Bulls Say
2025 Revenue Rebound (+47.7% YoY)A sustained top-line recovery of +47.7% in 2025 indicates improving commercial traction for marketed products and/or partnership revenues. Over 2–6 months this provides a more credible revenue base to support scale-up of sales, R&D funding and reduces dependence on short-term financing.
Improved Leverage (debt-to-equity ~0.57)Declining debt-to-equity to ~0.57 shows the capital structure has become less stretched, lowering interest and refinancing pressure. This improved leverage gives management more flexibility to fund clinical programs and commercialization without immediate dilutive capital raises, improving medium-term stability.
Diversified Revenue Model: Product Sales + LicensingHaving product sales plus licensing/milestones and potential services creates multiple cash and value pathways. Structural diversification reduces single-product dependency, allowing milestone or royalty inflows to offset operational burn and support long-term development sequencing.
Bears Say
Sharp Gross Margin Compression (~17% In 2025)A collapse in gross margin to ~17% signals structural pricing, cost or product-mix issues that erode the ability to convert revenue into sustainable profits. Even with revenue growth, low gross margins make durable profitability and self-funding of R&D/commercial ops difficult without structural changes.
Persistent Negative Operating And Free Cash FlowConsistent negative OCF/FCF and ~-328M in 2025 indicate the company funds operations externally. Over months this raises financing and dilution risk, constrains investment in trials and commercialization, and increases vulnerability if capital markets tighten or partners delay payments.
Deep Net Losses And Very Weak Returns (net Margin ~-162%, ROE ~-69%)Extremely negative net margins and ROE reflect inability to generate shareholder returns and erode equity value. Structurally, this limits reinvestment capacity, strains credibility with partners/investors and implies a prolonged path to sustainable profitability unless margins materially improve.
CStone Pharmaceuticals News
2616 FAQ
What was CStone Pharmaceuticals’s price range in the past 12 months?
CStone Pharmaceuticals lowest stock price was HK$3.06 and its highest was HK$13.15 in the past 12 months.
What is CStone Pharmaceuticals’s market cap?
CStone Pharmaceuticals’s market cap is HK$12.38B.
When is CStone Pharmaceuticals’s upcoming earnings report date?
CStone Pharmaceuticals’s upcoming earnings report date is Aug 20, 2026 which is in 91 days.
How were CStone Pharmaceuticals’s earnings last quarter?
CStone Pharmaceuticals released its earnings results on Mar 26, 2026. The company reported -HK$0.138 earnings per share for the quarter, missing the consensus estimate of -HK$0.057 by -HK$0.08.
Is CStone Pharmaceuticals overvalued?
According to Wall Street analysts CStone Pharmaceuticals’s price is currently Undervalued.
Does CStone Pharmaceuticals pay dividends?
CStone Pharmaceuticals does not currently pay dividends.
What is CStone Pharmaceuticals’s EPS estimate?
CStone Pharmaceuticals’s EPS estimate is -0.22.
How many shares outstanding does CStone Pharmaceuticals have?
CStone Pharmaceuticals has 1,600,249,100 shares outstanding.
What happened to CStone Pharmaceuticals’s price movement after its last earnings report?
CStone Pharmaceuticals reported an EPS of -HK$0.138 in its last earnings report, missing expectations of -HK$0.057. Following the earnings report the stock price went up 0.145%.
Which hedge fund is a major shareholder of CStone Pharmaceuticals?
Currently, no hedge funds are holding shares in HK:2616
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CStone Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
290.90%
12-Months-Change
Fundamentals
Return on Equity
-64.19%
Trailing 12-Months
Asset Growth
2.02%
Trailing 12-Months
Company Description
CStone Pharmaceuticals
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma. Its products also comprise CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Shanghai, China.
2616 Stock 12 Month Forecast
Average Price Target
HK$9.87
▲(84.83% Upside)
Technical Analysis
Alphamab Oncology
―
HBM Holdings Ltd.
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
Abbisko Cayman Limited
―
Shandong Boan Biotechnology Company., Limited. Class H
―
Options Prices
Currently, No data available
---